![]()
|
|
||||||||
J. Biol. Chem., Vol. 279, Issue 16, 15938-15945, April 16, 2004
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||



¶||
From the
Center for Molecular Neurobiology,
Ohio State Biochemistry Program, and the ¶Department of Molecular and Cellular Biochemistry, Ohio State University College of Medicine and Public Health, Columbus, Ohio 43210
Tau hyperphosphorylation precedes neuritic lesion formation in Alzheimer's disease, suggesting it participates in the tau fibrillization reaction pathway. Candidate tau protein kinases include members of the casein kinase 1 (CK1) family of phosphotransferases, which are highly overexpressed in Alzheimer's disease brain and colocalize with neuritic and granulovacuolar lesions. Here we characterized the contribution of one CK1 isoform, Cki
, to the phosphorylation of tau at residues Ser202/Thr205 and Ser396/Ser404 in human embryonic kidney 293 cells using immunodetection and fluorescence microscopy. Treatment of cells with membrane permeable CK1 inhibitor 3-[(2,3,6-trimethoxyphenyl)methylidenyl]-indolin-2-one (IC261) lowered occupancy of Ser396/Ser404 phosphorylation sites by >70% at saturation, suggesting that endogenous CK1 was the major source of basal phosphorylation activity at these sites. Overexpression of Cki
increased CK1 enzyme activity and further raised tau phosphorylation at residues Ser202/Thr205 and Ser396/Ser404 in situ. Inhibitor IC261 reversed tau hyperphosphorylation induced by Cki
overexpression. Co-immunoprecipitation assays showed direct association of tau and Cki
in situ, consistent with tau being a Cki
substrate. Cki
overexpression also produced a decrease in the fraction of bulk tau bound to detergent-insoluble microtubules. These results suggest that Cki
phosphorylates tau at sites that modulate tau/microtubule binding, and that the expression pattern of Cki
in Alzheimer's disease is consistent with it playing an important role in tau aggregation.
Received for publication, December 23, 2003 , and in revised form, January 26, 2004.
* This work was supported by National Institutes of Health Grant AG14452 (to J. K.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
|| To whom correspondence should be addressed: Center for Neurobiotechnology, 1060 Carmack Rd., Columbus, OH 43210. Tel.: 614-688-5899; Fax: 614-292-5379; E-mail: kuret.3{at}osu.edu.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
D. P. Hanger, H. L. Byers, S. Wray, K.-Y. Leung, M. J. Saxton, A. Seereeram, C. H. Reynolds, M. A. Ward, and B. H. Anderton Novel Phosphorylation Sites in Tau from Alzheimer Brain Support a Role for Casein Kinase 1 in Disease Pathogenesis J. Biol. Chem., August 10, 2007; 282(32): 23645 - 23654. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Bandyopadhyay, G. Li, H. Yin, and J. Kuret Tau Aggregation and Toxicity in a Cell Culture Model of Tauopathy J. Biol. Chem., June 1, 2007; 282(22): 16454 - 16464. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Ding, T. A. Matthews, and G. V. W. Johnson Site-specific Phosphorylation and Caspase Cleavage Differentially Impact Tau-Microtubule Interactions and Tau Aggregation J. Biol. Chem., July 14, 2006; 281(28): 19107 - 19114. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Necula and J. Kuret Pseudophosphorylation and Glycation of Tau Protein Enhance but Do Not Trigger Fibrillization in Vitro J. Biol. Chem., November 26, 2004; 279(48): 49694 - 49703. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |